MPLT (MapLight Therapeutics) Accounts Payable: $3.19 Mil (As of Mar. 2026)


MPLT MapLight Therapeutics Inc MPLT
14 GF Score
Price $37.11
! 4 Warning Signs
View Full Analysis

What is MapLight Therapeutics Accounts Payable?

MapLight Therapeutics MPLT +3.09% 14 Accounts Payable is $3.19 Mil as of Mar. 2026. GuruFocus rates MPLT with a GF Score™ of 14/100. The stock has 4 warning signs investors should review.

MapLight Therapeutics's Accounts Payable for the quarter that ended in Mar. 2026 was $3.19 Mil.

MapLight Therapeutics's quarterly Accounts Payable increased from Sep. 2025 ($2.45 Mil) to Dec. 2025 ($3.29 Mil) but then declined from Dec. 2025 ($3.29 Mil) to Mar. 2026 ($3.19 Mil).

MapLight Therapeutics's annual Accounts Payable declined from Dec. 2023 ($3.25 Mil) to Dec. 2024 ($1.91 Mil) but then increased from Dec. 2024 ($1.91 Mil) to Dec. 2025 ($3.29 Mil).

MapLight Therapeutics Accounts Payable Related Terms

MapLight Therapeutics Accounts Payable Historical Data

* Premium members only.

The historical data trend for MapLight Therapeutics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MapLight Therapeutics Accounts Payable Chart

MapLight Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Accounts Payable
3.60 3.25 1.91 3.29

MapLight Therapeutics Quarterly Data
Dec22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.86 2.10 2.45 3.29 3.19
MPLT
14GF Score
MapLight Therapeutics Inc MPLT
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MapLight Therapeutics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $3.19 Mil mean?
MapLight Therapeutics (MPLT) has a Accounts Payable of $3.19 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on MapLight Therapeutics and its competitors.
Is MapLight Therapeutics' Accounts Payable too high?
MapLight Therapeutics' current Accounts Payable is $3.19 Mil. Overall, MapLight Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does MapLight Therapeutics' Accounts Payable compare to COAG and CAPR?
MapLight Therapeutics' Accounts Payable of $3.19 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on MapLight Therapeutics and its competitors. MapLight Therapeutics's current Accounts Payable is $3.19 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MapLight Therapeutics stock overvalued right now?
MapLight Therapeutics (MPLT) has a current Accounts Payable of $3.19 Mil. The current Accounts Payable is $3.19 Mil. MapLight Therapeutics' overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For MapLight Therapeutics (MPLT), the current Accounts Payable is $3.19 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MapLight Therapeutics Business Description

Address 800 Chesapeake Drive, Redwood City, CA, USA, 94063
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.
14GF Score

Get the complete analysis for MPLT

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$37.11
Price